Fingolimod for the treatment of relapsing multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 11, Issue 2, 2011, Pages 165-183

  Jeffery, Douglas R ^a   Markowitz, Clyde E ^b   Reder, Anthony T ^c   Weinstock Guttman, Bianca ^d   Tobias, Kathy ^e  

^a Multiple Sclerosis and Movement Disorders Center at Advance Neurology at Cornerstone Health Care   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d JACOBS NEUROLOGICAL INSTITUTE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Administration recommendations; Efficacy; Fingolimod; Immunomodulatory; Mechanism of action; Oral; Relapsing remitting multiple sclerosis; Safety; Sphingosine 1 phosphate receptor

Indexed keywords

ATROPINE; BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; GILENYA; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 17; ISOPRENALINE; MITOXANTRONE; NATALIZUMAB; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AMENORRHEA; APPENDICITIS; ARTHRALGIA; ARTICLE; ATRIOVENTRICULAR BLOCK; BACKACHE; BASAL CELL CARCINOMA; BLOOD BRAIN BARRIER; BRADYCARDIA; BRAIN DISEASE; BRAIN SIZE; BRONCHITIS; CARDIOTOXICITY; CELL PROLIFERATION; COUGHING; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENTEROCOLITIS; FACIAL HERPES ZOSTER; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HEART RATE; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INCIDENCE; INFECTION; INFERTILITY; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; LEUKEMIA; LEUKOPENIA; LIVER FUNCTION; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MELANOMA; MEMORY T LYMPHOCYTE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNGEAL PAIN; PAIN; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; RECURRENT DISEASE; RETINA MACULA EDEMA; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUS BRADYCARDIA; SINUSITIS; SPIROMETRY; SQUAMOUS CELL CARCINOMA; SYNCOPE; T LYMPHOCYTE ACTIVATION; THORAX PAIN; URINARY TRACT INFECTION; VERTIGO; VISUAL ACUITY; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 79951597957     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.193     Document Type: Article

References (101)

1. Anderson DW, Ellenberg JH, Leventhal CM et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol. 31(3), 333-336 (1992).
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343(13), 938-952 (2000).
3. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112(Pt 1), 133-146 (1989). (Pubitemid 19056478)
4. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61(11), 1528-1532 (2003). (Pubitemid 37505574)
5. Bejaoui K, Rolak LA. What is the risk of permanent disability from a multiple sclerosis relapse? Neurology 74(11), 900-902 (2010).
6. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247-269 (2008).
7. Scalfari A, Neuhaus A, Degenhardt A et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133(Pt 7), 1914-1929 (2010).
8. Kappos L, Traboulsee A, Constantinescu C et al. Long-term subcutaneous interferon b-1a therapy in patients with relapsing- remitting MS. Neurology 67(6), 944-953 (2006). (Pubitemid 44454583)
9. Avonex® (interferon b-1a) IM Injection. Prescribing Information. Biogen Idec Inc., Cambridge, MA, USA (2008).
10. Novantrone (mitoxantrone) Injection. Prescribing Information. EMD Serono, Inc., Rockland, MA, USA (2010).
11. Betaseron® (interferon b-1a) SC Injection. Prescribing Information. Bayer HealthCare Pharmaceuticals Inc., Montville, NJ, USA (2009).
12. Extavia® (interferon b-1b). Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2009).
13. Copaxone® (glatiramer acetate) Injection. Prescribing Information. Teva Neuroscience, Inc., Kansas City, MO, USA (2009).
14. Río J, Montalban X. Interferon-b1b in the treatment of multiple sclerosis. Expert Opin. Pharmacother. 6(16), 2877-2886 (2005).
15. Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 402-415 (2010).
16. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 70(12), 1545-1577 (2010).
17. Interferon b-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43(4), 655-661 (1993).
18. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon b-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39(3), 285-294 (1996). (Pubitemid 26100751)
19. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7), 1268-1276 (1995).
20. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352(9139), 1498-1504 (1998).
21. Stone LA, Frank JA, Albert PS et al. Characterization of MRI response to treatment with interferon b-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 49(3), 862-869 (1997). (Pubitemid 27428037)
22. Panitch H, Miller A, Paty D, Weinshenker B. Interferon b-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63(10), 1788-1795 (2004). (Pubitemid 39532370)
23. Ford C, Goodman AD, Johnson K et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult. Scler. 16(3), 342-350 (2010).
24. Zivadinov R, Reder AT, Filippi M et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71(2), 136-144 (2008).
25. Treadaway K, Cutter G, Salter A et al. Factors that influence adherence with disease-modifying therapy in MS. J. Neurol. 256(4), 568-576 (2009).
26. Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L. Adherence to interferon-b treatment and results of therapy switching. J. Neurol. Sci. 259(1-2), 104-108 (2007). (Pubitemid 47031209)
27. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350), 2018-2025 (2002). (Pubitemid 36026580)
28. Marriott JJ, Miyasaki JM, Gronseth G, O Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74(18), 1463-1470 (2010).
29. Rudick RA, Sandrock A. Natalizumab: a4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurother. 4(4), 571-580 (2004). (Pubitemid 38890585)
30. Goodin DS, Cohen BA, O Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71(10), 766-773 (2008).
31. Kappos L, Radue EW, O Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387-401 (2010).
32. Spiegel S, Milstien S. Sphingolipid metabolites: members of a new class of lipid second messengers. J. Membr. Biol. 146(3), 225-237 (1995).
33. Spiegel S, Cuvillier O, Edsall LC et al. Sphingosine-1-phosphate in cell growth and cell death. Ann. N. Y. Acad. Sci. 845, 11-18 (1998). (Pubitemid 28365296)
34. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol. Res. 47(5), 401-407 (2003). (Pubitemid 36379202)
35. Lee MJ, Van Brocklyn JR, Thangada S et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279(5356), 1552-1555 (1998). (Pubitemid 28217081)
36. Lee HY, Shin EH, Bae YS. Sphingosylphosphorylcholine stimulates human monocyte-derived dendritic cell chemotaxis. Acta Pharmacol. Sin. 27(10), 1359-1366 (2006).
37. Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102(10), 3665-3667 (2003). (Pubitemid 37409386)
38. Mizugishi K, Yamashita T, Olivera A et al. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell Biol. 25(24), 11113-11121 (2005). (Pubitemid 41747151)
39. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73, 321-354 (2004). (Pubitemid 39050372)
40. Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296(5566), 346-349 (2002). (Pubitemid 34303689)
41. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J. Cell Biochem. 92(5), 913-922 (2004). (Pubitemid 44264241)
42. Watterson K, Sankala H, Milstien S, Spiegel S. Pleiotropic actions of sphingosine-1-phosphate. Prog. Lipid Res. 42(4), 344-357 (2003). (Pubitemid 36411690)
43. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33(2), 91-101 (2010).
44. Chiba K, Yanagawa Y, Masubuchi Y et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160(10), 5037-5044 (1998). (Pubitemid 28215340)
45. Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972), 355-360 (2004). (Pubitemid 38133663)
46. Yanagawa Y, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer s patches by FTY720-induced lymphocyte homing. Immunology 95(4), 591-594 (1998). (Pubitemid 28559152)
47. Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 18(3), 551-553 (2004).
48. Mehling M, Lindberg RL, Kuhle J et al. Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis. Mult. Scler. 14(1 Suppl.), S234 (Abstract P697) (2008).
49. Tzartos JS, Friese MA, Craner MJ et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172(1), 146-155 (2008). (Pubitemid 351186376)
50. Kebir H, Kreymborg K, Ifergan I et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13(10), 1173-1175 (2007). (Pubitemid 47530640)
51. Mehling M, Lindberg R, Raulf F et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75(5), 403-410 (2010).
52. Brinkmann V, Metzler B, Matloubian H. The mode of action of fingolimod (FTY720), an oral sphingosine 1-phosphate receptor modulator that is highly effective in human multiple slcerosis (Phase II). Mult. Scler. 12, S100 (Abstract P374) (2006).
53. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4(7), 1019-1025 (2004). (Pubitemid 38868590)
54. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 8(12), 1295-1301 (2007). (Pubitemid 350131168)
55. Pinschewer DD, Ochsenbein AF, Odermatt B et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164(11), 5761-5770 (2000). (Pubitemid 30389819)
56. Hofmann M, Brinkmann V, Zerwes HG. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int. Immunopharmacol. 6(13-14), 1902-1910 (2006). (Pubitemid 44855701)
57. Schmouder R, Aradhye S, O Connor P, Kappos L. Pharmacodynamic effects of oral fingolimod (FTY72). Mult. Scler. 12(Suppl. 1), S101-S102 (Abstract P378) (2006).
58. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin. Investig. 70(7), 539-544 (1992).
59. Johnson TA, Shames I, Keezer M et al. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin. Immunol. 137(1), 15-20 (2010).
60. Jung CG, Kim HJ, Miron VE et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55(16), 1656-1667 (2007). (Pubitemid 47612852)
61. Gardell S, Choi JW, Herr D et al. Evidence for neural S1P receptor signaling in EAE and FTY720 efficacy. Mult. Scler. 13(2 Suppl.), S70 (Abstract P243) (2007).
62. Saini HS, Coelho RP, Goparaju SK et al. Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J. Neurochem. 95(5), 1298-1310 (2005). (Pubitemid 41779255)
63. Novgorodov AS, El Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. 21(7), 1503-1514 (2007). (Pubitemid 46684852)
64. Miron VE, Jung CG, Kim HJ et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 63(1), 61-71 (2008). (Pubitemid 351240552)
65. Barske C, Osinde M, Mir AK et al. FTY720 (fingolimod) enhances the number of immature and mature oligodendrocytes. Mult. Scler. 13(2 Suppl.), S148 (Abstract P498) (2007).
66. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther. 323(2), 626-635 (2007). (Pubitemid 350005137)
67. Toman RE, Payne SG, Watterson KR et al. Differential transactivation of sphingosine- 1-phosphate receptors modulates NGF-induced neurite extension. J. Cell Biol. 166(3), 381-392 (2004). (Pubitemid 39031241)
68. Kimura A, Ohmori T, Ohkawa R et al. Essential roles of sphingosine 1-phosphate/ S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25(1), 115-124 (2007). (Pubitemid 46052981)
69. Edsall LC, Pirianov GG, Spiegel S. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J. Neurosci. 17(18), 6952-6960 (1997). (Pubitemid 27427874)
70. Chin TY, Hwang HM, Chueh SH. Distinct effects of different calcium-mobilizing agents on cell death in NG108-15 neuroblastoma X glioma cells. Mol. Pharmacol. 61(3), 486-494 (2002).
71. Shinpo K, Kikuchi S, Moriwaka F, Tashiro K. Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons. Brain Res. 819(1-2), 170-173 (1999). (Pubitemid 29225471)
72. Deogracias R, Klein C, Matsumoto T et al. Expression of brain-derived neurotrophic factor is regulated by fingolimod (FTY720) in cultured neurons. Mult. Scler. 14(1 Suppl.), S243 (Abstract P728) (2008).
73. Balatoni B, Storch MK, Swoboda EM et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull. 74(5), 307-316 (2007). (Pubitemid 47368881)
74. Giovannoni G, Al-Izki S, Pryce G, Jackson S, Baker D. Control of chronic relapsing progressive EAE with fingolimod. Presented at: 60th Annual Meeting of the American Academy of Neurology, Chicago, IL, USA, April 12-17, 2008 (Poster presentation).
75. Rao TS, Lariosa-Willingham KD, Lin FF et al. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res. 990(1-2), 182-194 (2003). (Pubitemid 37244074)
76. Rao TS, Lariosa-Willingham KD, Lin FF et al. Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes. Int. J. Dev. Neurosci. 22(3), 131-135 (2004). (Pubitemid 38597128)
77. Mullershausen F, Craveiro LM, Shin Y et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1- phosphate receptors. J Neurochem 102(4), 1151-1161 (2007). (Pubitemid 47174238)
78. Yamagata K, Tagami M, Torii Y et al. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 41(2), 199-206 (2003). (Pubitemid 36262197)
79. Osinde M, Mullershausen F, Dev KK. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52(5), 1210-1218 (2007). (Pubitemid 46546406)
80. Rouach N, Pébay A, Même W et al. S1P inhibits gap junctions in astrocytes: involvement of Gi and Rho GTPase/ROCK. Eur. J. Neurosci. 23(6), 1453-1464 (2006).
81. Choi JW, Herr D, Kennedy G, Chun J. Astrocytic sphingosine 1-phosphate (S1P) receptor subtype 1 signalling influences levels of S1P and cytokines during experimental autoimmune encephalomyelitis and fingolimod (FTY720) intervention. Mult. Scler. 15, S58 (Abstract P227) (2009).
82. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355(11), 1124-1140 (2006). (Pubitemid 44394919)
83. O Connor P, Comi G, Montalban X et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a Phase II extension study. Neurology 72(1), 73-79 (2009).
84. Comi G, O Connor P, Montalban X et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult. Scler. 16(2), 197-207 (2010).
85. Tysabri (natalizumab) Injection. Prescribing Information. Biogen Idec Inc., Cambridge, MA, USA (2008).
86. Neutralizing antibodies during treatment of multiple sclerosis with interferon b-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/ MRI Analysis Group. Neurology 47(4), 889-894 (1996).
87. PRISMS-4: Long-term efficacy of interferon-b-1a in relapsing MS. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Neurology 56(12), 1628-1636 (2001).
88. Francis GS, Rice GP, Alsop JC. Interferon b-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65(1), 48-55 (2005). (Pubitemid 40967775)
89. Pachner AR, Warth JD, Pace A, Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon b: the INSIGHT study. Neurology 73(18), 1493-1500 (2009).
90. Calabresi PA, Giovannoni G, Confavreux C et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69(14), 1391-1403 (2007). (Pubitemid 47511460)
91. Giovannoni G, Barbarash O, Casset- Semanaz F et al. Safety and immunogenicity of a new formulation of interferon b-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult. Scler. 15(2), 219-228 (2009).
92. Foster CA, Howard LM, Schweitzer A et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 323(2), 469-475 (2007).
93. Gilenya (fingolimod) Capsules for Oral Use. Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2010).
94. The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, USA (2006).
95. Uhlig S, Gulbins E. Sphingolipids in the lungs. Am. J. Respir. Crit. Care Med. 178(11), 1100-1114 (2008).
96. Salvadori M, Budde K, Charpentier B et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant. 6(12), 2912-2921 (2006).
97. Tedesco-Silva H, Pescovitz MD, Cibrik D et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 82(12), 1689-1697 (2006). (Pubitemid 46035653)
98. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115(1), 84-105 (2007). (Pubitemid 46990553)
99. Chen E, Looman M, Laouri M et al. Burden of illness of diabetic macular edema: literature review. Curr. Med. Res. Opin. 26(7), 1587-1597 (2010).
100. Markomichelakis NN, Halkiadakis I, Pantelia E et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 111(5), 946-953 (2004). (Pubitemid 38586689)
101. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon b therapy in relapsing-remitting multiple sclerosis. Eur. Neurol. 59(3-4), 131-135 (2008). (Pubitemid 351301255)